Chronic Kidney Disease Clinical Trial
— BASEOfficial title:
The BASE Study: Bicarbonate Administration to Stabilize eGFR
Verified date | October 2020 |
Source | The Cleveland Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The two doses of sodium bicarbonate being tested are 0.5 and 0.8 mEq/kg-lean body weight (LBW) per day. Sodium bicarbonate, also known as baking soda, may help prevent kidney failure in people with chronic kidney disease. However, the dose to prescribe in order to test this possibility in a clinical trial is uncertain. The BASE pilot clinical trial will help determine the best dose of sodium bicarbonate to prescribe in a future study that will test the long-term safety and efficacy of sodium bicarbonate as a treatment to preserve kidney function in individuals with chronic kidney disease.
Status | Completed |
Enrollment | 194 |
Est. completion date | June 2018 |
Est. primary completion date | January 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Serum bicarbonate 20-28 mEq/L at screening (the average of the two most recent values in Baseline must be 20-28 mEq/L prior to randomization) 2. Moderate to severe chronic kidney disease (CKD) at the time of screening, defined as one of the following: - eGFR 20-44 ml/min/1.73m2 or - eGFR 45-59 ml/min/1.73m2 plus random urinary albumin:creatinine (ACR) =100 mg/gm 3. Blood pressure <160/100 mm Hg at screening (must be <150/100 mm Hg prior to randomization) 4. Lean body weight 38.0-96.0 kg at the time of screening 5. Age allowing legal consent without parental involvement (18-21 years, depending on individual state regulations) 6. Able to provide consent 7. Able to travel to study visits 8. Able to read English 9. In the opinion of the site investigator, willing and able to follow the study treatment regimen and comply with the site investigator's recommendations 10. In the opinion of the site investigator, medically stable Exclusion Criteria: 1. Use of chronic daily oral alkali (such as sodium bicarbonate, sodium citrate, potassium citrate, etc) with one exception: calcium carbonate =1500 mg/day is allowed, as some will take this for the indication of bone health 2. On five or more antihypertensive and/or diuretic agents, regardless of the indication 3. Serum potassium <3.3 or =5.5 mEq/L at screening (must be 3.5-5.5 mEq/L prior to randomization) 4. Self-reported vegetarian 5. New York Heart Association Class 3 or 4 heart failure symptoms, known left ventricular ejection fraction =30%, or hospital admission for heart failure within the past 3 months 6. Frequent urinary tract infections (=2 in the past year) 7. Presence of indwelling urinary catheter or urinary conduit (such as neobladder or urostomy) 8. Factors judged to limit adherence to interventions (e.g., alcoholism, history of missing clinic visits, chronic gastrointestinal disorder that makes compliance with the intervention unreliable) 9. Organ transplant recipients (excluding cornea) 10. Active glomerular disease requiring or potentially requiring immunosuppressive treatment 11. Chronic immunosuppressive therapy (for =3 months) for any indication. This does not include oral steroids <10 mg per day, inhaled steroids, or topical steroids 12. Anticipated initiation of dialysis or kidney transplantation within 12 months as assessed by the site investigator 13. Current participation in another interventional research study 14. Malignancy requiring therapy within 2 years (basal or squamous cell skin carcinoma and localized prostate cancer are exempted) 15. Pregnancy or planning to become pregnant or currently breast-feeding. Women of childbearing potential (pre-menopausal and not surgically sterilized) will have urine pregnancy test before enrollment. 16. Life expectancy <12 months as determined by the site investigator 17. Institutionalized individuals, including prisoners and nursing home residents 18. Plans to leave the immediate area within the next 12 months 19. Routinely leaves town for multiple weeks each year such that protocol visits would be missed 20. Chronic use of supplemental oxygen 21. Use of both angiotensin-converting-enzyme inhibitor (ACEI) and Angiotensin II Receptor Blockers (ARBs) |
Country | Name | City | State |
---|---|---|---|
United States | Northwestern University | Chicago | Illinois |
United States | Data Coordinating Center; Cleveland Clinic Foundation; Quantitative Health Sciences; 9500 Euclid Avenue | Cleveland | Ohio |
United States | Denver Nephrology Research | Denver | Colorado |
United States | University of Utah | Salt Lake City | Utah |
United States | Utah VA | Salt Lake City | Utah |
United States | Baylor/Scott & White | Temple | Texas |
United States | George Washington University | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Jennifer Gassman, PhD | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The Cleveland Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants in Each Dose Arm Prescribed (i) Full Randomized Sodium Bicarbonate Dose at End of 28 Weeks & (ii) at Least 25% of Randomized Sodium Bicarbonate Dose at End of 28 Weeks as a Proportion of the Number Randomized to That Group | The prescribed dose for each participant at the end of 28 weeks will be determined by the safety and tolerability of each dose during the intervention period. The primary assessments will examine the percentage of participants in each dose arm who are prescribed (i) the full randomized sodium bicarbonate dose according to the protocol at the end of 28 weeks and (ii) at least 25% of the randomized sodium bicarbonate dose according to the protocol at the end of 28 weeks. The two doses of sodium bicarbonate being tested are 0.5 and 0.8 mEq/kg-lean body weight per day. | Baseline, 28 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |